// App-Quantinova.ai

POS0107 (2022) : ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES

Researchers

Presenter

  • R. Alten

Principal Investigators

  • C. Rauch

  • M. Chartier

  • M. T. Nurmohamed

  • S. Connolly

  • M. H. Buch

  • P. Peichl

  • X. Mariette

  • Y. Patel

  • S. Marsal

  • R. Caporali

  • H. Griffiths

  • R. Sanmart

  • B. Bannert

  • Y. Elbez

  • K. Lozenski

Medical Centers

  • Schlosspark-Klinik University, Department of Internal Medicine, Rheumatology, Berlin, Germany

  • Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany

  • Bristol Myers Squibb, MESP France - Market Access, Rueil-Malmaison, France

  • ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • School of Biological Sciences The University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom

  • Hietzing Hospital, Department of Internal Medicine, Vienna, Austria

  • Université Paris-Saclay, AP-HP, Hospital Bicêtre, INSERM UMR1184, Department of Rheumatology, Le Kremlin Bicêtre, France

  • Hull Royal Infirmary, Rheumatology, Hull, United Kingdom

  • University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy

  • G. Pini Hospital, Clinical Rheumatology Unit, Milan, Italy

  • University Hospital Geelong, Barwon Rheumatology Service, Geelong, Australia

  • Hospital Clinic de Barcelona, Radiology Department, Barcelona, Spain

  • Universitätsspital Basel, Rheumatologische Universitätsklinik, Basel, Switzerland

  • Signifience, Biostatistics, Paris, France

  • Bristol Myers Squibb, Medical Immunology, Princeton, United States of America

Locations

  • Germany

  • France

  • Netherlands

  • United States

  • United Kingdom

  • Austria

  • Spain

  • Italy

  • Australia

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Abatacept

Outcome

  • N/A

Study Design

  • Observational

Phase

  • N/A

Study Id's

  • NCT02109666

  • NCT02090556

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved